PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10264743

Utilizing the computer for a hospital bid program.

M Caufman
View original source ↗Export metadata ↓

Abstract

The goals of a computerized bid program include acquisition of pharmaceuticals at lowest possible cost, guaranteeing prices for a fixed period of time, having the ability to provide budget and patient charge information, decreased payroll hours and expenses vs. a manual system, and having the ability to retrieve data for accounting and purchasing procedures. These goals can be obtained by separating the bid procedure into five operations, which are identifying the pharmaceuticals to bid, preparing a vendor bid list, tabulating the bids received, selection of awarded bids, and vendor notification of awarded bids.

Explore related subjects

CommerceComputersFloridaHospital Bed Capacity, 300 to 499Pharmacy Service, HospitalPurchasing, HospitalJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Caufman. 1984. Utilizing the computer for a hospital bid program.. https://pubmed.ncbi.nlm.nih.gov/10264743/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2005

Examining the link between price regulation and pharmaceutical R&D investment.

This paper examines the link between price regulation and pharmaceutical research and development (R&D) investment. I identify two mechanisms through which price regulation may exert an influence on R&D: an expected-profit effect and a cash-flow effect. Using established models of the determinants of pharmaceutical R&D, I exploit a unique fact to quantify firm exposure to pharmaceutical price regulation: relative to the rest of the world, the U.S. pharmaceutical market is largely unregulated with respect to price. Using this fact within the context of a system of quasi-structural equations, I simulate how a new policy regulating pharmaceutical prices in the U.S. will affect R&D investment. I find that such a policy will lead to a decline in industry R&D by between 23.4 and 32.7%. This prediction, however, is accompanied by several caveats. Moreover, it says nothing about the implications for social welfare; therefore, these issues are also discussed.

Commerce↗
PubMed2005

The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s.

We analyze the effect of price regulation on delays in launch of new drugs. Because a low price in one market may 'spill-over' to other markets, through parallel trade and external referencing, manufacturers may rationally prefer longer delay or non-launch to accepting a relatively low price. We analyze the launch in 25 major markets, including 14 EU countries, of 85 new chemical entities (NCEs) launched between 1994 and 1998. Each NCE's expected price and market size in a country are estimated using lagged average price and market size of other drugs in the same (or related) therapeutic class. We estimate a Cox proportional hazard model of launch in each country, relative to first global launch. Only 55% of the potential launches occur. The US leads with 73 launches, followed by Germany (66) and the UK (64). Only 13 NCEs are launched in Japan, 26 in Portugal and 28 in New Zealand. The results indicate that countries with lower expected prices or smaller expected market size have fewer launches and longer launch delays, controlling for per capita income and other country and firm characteristics. Controlling for expected price and volume, country effects for the likely parallel export countries are significantly negative.

Commerce↗